Elicio Therapeutics reports Q3 results
Elicio Therapeutics Q3 results: narrower net loss, lower R&D spending, and $30.9M in cash. - Elicio Therapeutics press release (ELTX): Q3 Net loss per share of $0.30, compared with $0.60 Y/Y - Research and development expenses decreased 3% Y/Y to $4.9M - General and administrative expenses increased…